NKTX
Nkarta, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 28 ▲ Three major passive institutions, Morgan Stanley, Wells Fargo, and U…
- Mar 25 ▼ Nkarta, Inc. announced an at-the-market (ATM) offering program allow…
- Mar 25 ▼ Nkarta, Inc. (NKTX) has filed a shelf registration (S-3) to raise up…
- Apr 6 ▼ Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effect…
- Apr 15 ▲ Nkarta announced FDA agreement on protocol amendments for its Ntrust…
- Apr 15 FDA: Nkarta Announces FDA Agreement on Outpatient Dosing of NKX…
- Jun 18 ▼ 1 insider sell $4.8K at $2.71
- Aug 10 ▼ Nkarta reported Q2 2026 net loss of $0.54 per share, significantly m…
- Nov 9 ▲ Nkarta reported initial Phase 1/2 clinical data for NKX019, an allog…
- Nov 9 FDA: Nkarta Announces Initial Clinical Data for NKX019 in Myosi…
- Nov 9 ▲ Nkarta announced positive initial clinical data from its Ntrust prog…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $4.8K.
- InstitutionsMIXED
Q3 2026: 18 added (0 new), 16 trimmed or exited.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.380 → −$0.455 over 90 days.
- Short sellersSTEADY
Short interest +12.1% to 3.84M shares. 2.9 days to cover, ≈5.3% of shares.
- TrendDOWNTREND
44% below its 50-day average. New closing low $1.19 on Nov 13.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $2.1M |
| MORGAN STANLEY | ADD | $916.8K |
| Qube Research & Technologies Ltd | ADD | $510.8K |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $373.8K |
| Nuveen, LLC | TRIM | $326.7K |
| Empowered Funds, LLC | ADD | $283.4K |
| SEI INVESTMENTS CO | ADD | $192.7K |
| IEQ CAPITAL, LLC | TRIM | $164.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +809%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Needham REITERATE | Buy |
| Aug 14, 2026 | Stifel MAINTAIN | Buy |
| Aug 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
HASTINGS PAUL J Chief Executive Officer Jun 18, 2026 | SELL | $4.8K |
Thedinga Angela Director Jun 10, 2026 | AWARD | 37,000 sh |
PATTERSON LEONE D Director Jun 10, 2026 | AWARD | 37,000 sh |
Dybbs Michael Director Jun 10, 2026 | AWARD | 37,000 sh |
Scheiner Zachary Director Jun 10, 2026 | AWARD | 37,000 sh |
Vratsanos George Director Jun 10, 2026 | AWARD | 37,000 sh |
George Simeon Director Jun 10, 2026 | AWARD | 37,000 sh |
Behbahani Ali Director Jun 10, 2026 | AWARD | 37,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.46 | -$0.48–-$0.43 | -13.7% | $0.00 |
| Next Q | -$0.42 | -$0.42–-$0.42 | -16.7% | $0.00 |
| Current FY | -$1.82 | -$1.84–-$1.81 | -6.9% | $0.00 |
| Next FY | -$1.51 | -$1.72–-$1.27 | +13.7% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 3 press releases · 2 bullish · 5 bearish · 3 neutral- BULLISH 8-KNov 9, 2026
Nkarta reported initial Phase 1/2 clinical data for NKX019, an allogeneic CAR NK cell therapy, in…
Watch for upcoming FDA interactions to define registrational pathways and for 1H 2027 data on additional follow-up and registrational dose selection (4B vs 6B cells/dose). The compressed dosing…
- BULLISH PRESS RELEASENov 9, 2026
Nkarta announced positive initial clinical data from its Ntrust program for NKX019 in myositis and…
The strong efficacy and safety data support NKX019's potential as a differentiated CAR NK therapy in autoimmune disease. Watch for FDA meeting outcomes and registrational dose selection in H1 2027…
- NEUTRAL 8-KNov 6, 2026
Nkarta filed an 8-K announcing a webcast on November 9, 2026 to review initial clinical data for…
The webcast on November 9 will disclose initial clinical data for NKX019 in autoimmune indications. The data's safety and efficacy profile will determine the next catalyst for the stock.
- NEUTRAL 8-KNov 5, 2026
Cash burn continued with cash and investments declining to $216.0 million from $243.2 million at…
The ACR Convergence 2026 presentations (Nov 8-11) are the primary near-term catalyst. Efficacy and safety data from the Ntrust trials in myositis and systemic sclerosis will determine whether…
All NKTX filing & press-release reports (13)
- 8-K reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportNov 6, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportApr 15, 2026
- EFFECT reportApr 6, 2026
- 8-K reportMar 25, 2026
- S-3 reportMar 25, 2026
- PRESS-RELEASE reportMar 25, 2026
- INST-CLUSTER reportFeb 28, 2026